An international group of researchers, including Avivia CEO Hans Platteeuw, believe there is ample evidence that antimalarial drugs can be used to treat COVID-19 and that they should be assessed for their efficacy in clinical trials.
The research group, from institutions across Europe, Asia and Africa, point to a combination of the drugs artesunate and pyronaridine as the most promising.
November 6, 2020
The public-private consortium to run this project, involves leading academic groups and for-profit parties with a track record in drug discovery and development, has ample knowledge in medicinal chemistry and virology. The development of an effective treatment and prophylactic for COVID-19 will have a profound social and economic impact in the current times. Additionally, a broad spectrum antiviral will help to contain/curb future epidemic coronavirus outbreaks and to treat future patients.
June 16, 2020
With the current corona virus, face caps and disinfectant soap and hand gel are hardly available in the stores. Although you can discuss the usefulness of face masks, washing your hands regularly is an effective way to reduce the odds of getting sick. If water isn’t available a hand disinfection spray for the road is very useful.
March 2, 2020
TT4CL (Targeted treatment for cutaneous leishmaniasis) is a new Horizon 2020-funded project which aims to reduce the burden of Neglected Infectious Diseases (NID) and its social and economic impacts. Horizon 2020, the European Union’s (EU) research and innovation programme, helps to bridge the gap between preclinical and clinical development and thus helps to advance promising new drug candidates along the development pipeline. The TT4CL consortium, which brings together partners from academia and industry in Europe and disease-endemic countries, has been awarded EUR3.75 million to develop an oral treatment, D121, against one of the most neglected tropical diseases, cutaneous leishmaniasis.
July 16, 2019
Avivia B.V. is pleased to announce the expansion of its Business Development activities by the appointment of Marcel Langoor, PhD.
April 3, 2019
Marleen De Vriese and Hans Platteeuw are attending this weeks’ biannual meeting on Buruli Ulcer and Skin NTD’s at the WHO headquarters in Geneva (Switzerland).
March 25, 2019
The DDF Summit brings together leading formulation development, drug delivery and device development professionals from both industry and academia to share and discuss their latest work. Avivia will also be present there! Don't hesitate to arrange a meeting in advance by sending us a message or giving us a call!
February 14, 2019
The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.
NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties. At a later stage, the NADP will provide Intellectual Property Vouchers, Value Proposition Vouchers and Lead Development Vouchers.
May 1, 2018
Avivia/Excipia will be present as exhibitor on the 7th annual conference on pharmaceutical excipients.
The event will be organized by IPEC Europe and APV on 18-19 September 2018 in Cologne, Germany
The conference will focus on “hot topics” in the area of excipient regulation and technology.
During the conference and workshops topics like contamination in excipients, requirements for excipients, implementation of GMP in an excipient manufacturing site, supplier qualification and auditing, analytical data and certificates of analysis provided by suppliers of excipients will be discussed.
April 3, 2018
The world over, members of the Reproductive Health Supplies Coalition work tirelessly to broaden access to a range of affordable, quality contraceptives. In March, we will gather in Brussels to share our successes and, in particular, to celebrate the advances towards supply security in francophone Africa. This region boasts some of the world’s greatest reproductive health successes but also some of the most troubling statistics and seemingly intractable challenges.
As a new member of this coalition, Avivia is committed to making a valuable contribution.
February 20, 2018
M-building – Novio Tech Campus
6534 AT Nijmegen, The Netherlands
Email info [at] avivia.nl
Phone - Reception +31 (0)6-1968-6732